Literature DB >> 10772986

Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodominant region of gp41.

M Viveros1, C Dickey, J P Cotropia, G Gevorkian, C Larralde, K Broliden, M Levi, A Burgess, C Cao, D B Weiner, M G Agadjanyan, K E Ugen.   

Abstract

Previously, we generated human monoclonal antibodies using peripheral blood mononuclear cells from an asymptomatic human immunodeficiency virus type 1 (HIV-1)-seropositive donor. One of these monoclonal antibodies (designated clone 3, CL3) recognized 10 amino acids (GCSGKLICTT) within the immunodominant region (cluster I) of the transmembrane envelope glycoprotein gp41 and neutralized infection of target cells with different laboratory isolates. Because the epitope recognized by CL3 has two cysteine residues that could potentially produce a disulfide loop in gp41, we analyzed binding of our monoclonal antibody to the cyclic and linear motif of the peptide sequence IWGCSGKLICTTAVP (residues 600-614). The CL3 antibody did not bind to the synthetic cyclic peptide but did recognize the linear form. Two polyclonal rabbit sera against both the linear and cyclic peptides were then generated. Both antisera bound to viral glycoproteins gp41 and gp160, but neither sera neutralized HIV-1 laboratory isolates. Using a set of alanine-substituted IWGCSGKLICTTAV peptides, we analyzed binding of polyclonal antisera and CL3. The profile of binding of polyclonal antisera to these peptides was different from that of CL3 to the same peptides. This suggests that CL3 recognized a unique neutralizable core epitope, which was not immunogenic in either the cyclic or the linear IWGCSGKLICTTAVP peptides used as immunogens in the rabbits. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10772986     DOI: 10.1006/viro.2000.0269

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

1.  Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity.

Authors:  John Pietzsch; Johannes F Scheid; Hugo Mouquet; Michael S Seaman; Christopher C Broder; Michel C Nussenzweig
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

2.  Identifiable biomarker and treatment development using HIV-1 long term non-progressor sera.

Authors:  Yuxia Hao; Ge Bai; Junping Wang; Longfeng Zhao; Kyle Sutherland; Jianfeng Cai; Chuanhai Cao
Journal:  BMC Immunol       Date:  2015-04-28       Impact factor: 3.615

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.